Navigation Links
King and Pain Therapeutics Announce REMOXY(R) NDA Update
Date:7/7/2009

BRISTOL, Tenn. and SAN MATEO, Calif., July 7 /PRNewswire-FirstCall/ -- King Pharmaceuticals, Inc. (NYSE: KG) and Pain Therapeutics, Inc. (Nasdaq: PTIE) today announced that on July 2, 2009, King met with the US Food and Drug Administration (FDA) to discuss the Complete Response Letter regarding the New Drug Application (NDA) for REMOXY(R). The outcome of this meeting provided King with a clear path forward to resubmit the REMOXY(R) NDA and to address all FDA comments in the Complete Response Letter.

King now anticipates the resubmission of the NDA could occur mid-year 2010. The Company believes the rate-limiting step is the generation of six-month stability data, and no new clinical trials are required. King remains committed to the development and commercialization of REMOXY(R), and looks forward to working closely with the FDA toward approval of the product.

About REMOXY(R)

REMOXY, an investigational drug, is a unique, long-acting oxycodone formulation for moderate-to-severe chronic pain designed to reduce potential risks of unintended use. In mid-2008, an NDA for REMOXY was accepted by the FDA and was granted Priority Review. In December 2008, Pain Therapeutics received a Complete Response Letter from the FDA. Subsequent to the receipt of the Complete Response Letter, King assumed full control of all activities related to the development of REMOXY(R).

About King Pharmaceuticals, Inc.

King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangement
'/>"/>

SOURCE King Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes
2. Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
3. Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
4. PTC Therapeutics Receives $2.6 Million in Government Grants
5. Cell Therapeutics on Preliminary List of Additions to Russell 3000(R) Index and Russell Global(R) Index
6. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
7. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
8. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
9. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
10. Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board
11. PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Jolla, CA (PRWEB) July 23, 2014 ... stem cell therapy in the US aimed at improving ... announced their newest clinical study for Parkinson’s disease. ... efficacy of stem cell therapy are paramount when providing ... This clinical study makes stem cell therapy accessible to ...
(Date:7/23/2014)... TEL AVIV, Israel , July 23, 2014 ... Ltd ., a portfolio company of Trendlines ... with one of Israel,s ... (Logo: http://photos.prnewswire.com/prnh/20140121/666259-a) , Valentis,s technology combines ... from plant pulp waste, with additional nanoparticles to ...
(Date:7/23/2014)... 2014 DuPont Pioneer announced today that ... president of Agricultural Biotechnology (ABT), effective July 21, 2014. ... most recently as president, chief executive officer and board ... in the seed and crop protection industry to this ... Schickler , president of DuPont Pioneer. “I am looking ...
(Date:7/23/2014)... 23, 2014 /PRNewswire/ - BioAmber Inc. (NYSE: ... sustainable chemicals, today announced that the underwriters of its ... to purchase an additional 420,000 shares of common ... per share, less underwriting discounts and commissions, in ... of 2,800,000 shares of common stock, bringing the ...
Breaking Biology Technology:StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3
...  inVentiv Health, Inc., offering best-in-class clinical, commercial and ... it has completed the acquisition of Kforce Clinical ... solutions to pharmaceutical, biotech and medical device companies, ... The transaction closed on March 30, 2012.  ...
... 3, 2012 Health Diagnostic Laboratory, Inc. (HDL, Inc.), ... of Scott Blackwell. Recently named Vice President of Corporate ... values of an advanced laboratory that is growing on ... http://photos.prnewswire.com/prnh/20120403/PH81634 )  "Scott comes to our ...
... N.J., April 3, 2012 Hamamatsu Corporation announces ... distributed through third-party dealers, will now be available ... the company is responsible for the sales, marketing, ... product line for new customers throughout North America. ...
Cached Biology Technology:inVentiv Health Completes Acquisition of Kforce Clinical Research 2inVentiv Health Completes Acquisition of Kforce Clinical Research 3inVentiv Health Completes Acquisition of Kforce Clinical Research 4Health Diagnostic Laboratory Names Scott Blackwell Vice President of Corporate Culture 2Hamamatsu Corporation Announces Exclusive Distribution of Its NanoZoomer Whole-Slide Scanners 2
(Date:7/23/2014)... ischemic preconditioning has been confirmed by many studies, ... study released in the Neural Regeneration Research ... Liu and co-workers from Tongji Hospital Affiliated to ... Technology, China performed cerebral ischemic preconditioning in rats ... the mechanism underlying the neuroprotective effect of ischemic ...
(Date:7/23/2014)... release is available in German . ... the Max Planck Institute of Molecular Cell Biology ... to capture detailed three-dimensional images of cardiac dynamics ... Selective Plane Illumination Microscopy (SPIM) and clever image ... beating heart. Furthermore, they have developed a method ...
(Date:7/22/2014)... July 22, 2014 Aware, Inc. (NASDAQ: ... today reported financial results for its second quarter ended June ... 2014 was $6.8 million, an increase of 53% compared to ... before patent related income in the second quarter of 2014 ... quarter of 2013. The increase in revenue and operating income ...
Breaking Biology News(10 mins):Unbreak my heart 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7
... American Association for Cancer Research will recognize 27 recipients of ... at the AACR 102nd Annual Meeting 2011, held here from ... AACR-Thomas J. Bardos Science Education Award for Undergraduate Students is ... the field of cancer research. The AACR is committed ...
... William Hamilton introduced Inclusive Fitness Theory to predict and ... gene expression. With its many successes, the theory became ... Harvard researchers challenged the theory in the prestigious journal, ... scores of scientists, including Edward Allen Herre and William ...
... March 25, 2011 The Barrett-Jackson Collector Car Auction in ... through the sale and resale of a special ... the 40th anniversary sports car (the first Corvette was made ... it could be sold Jan. 22 at Barrett-Jackson,s 40th anniversary ...
Cached Biology News:AACR awards AACR-Thomas J. Bardos Science Education Award for Undergraduate Students 2AACR awards AACR-Thomas J. Bardos Science Education Award for Undergraduate Students 3Is blood thicker than water? 2Sale of sports car benefits TGen cancer fund named for Jackson family 2
Adhesive seal-tab, for HybriWell™ hybridization sealing system *set of 400*...
...
... Kit contains choice of PDMS Stamps (3 ... / 200 micron squares or 100 um ... 10 mm lines, 3 PDMS nano-patterned stamps ... nm and pitch of 400 nm, or ...
...
Biology Products: